Introduction

    Santolecan Pharmaceuticals Limited Liability Company is a US-based startup company that focuses on discovery of innovative therapeutics to improve human health and help patients live a quality of life. Our company project was awarded 3rd place in the 2022 Harvard University “H-InnoPitch” International Start-Up Pitch Competition and 2nd place in the 2024 International Innovation Contest for Startup Entrepreneurs (Ranked 7th out of 1,400 projects worldwide), and the success of our drug candidate projects can benefit millions of patients. Currently, our company’s pan-RAS tumor candidate, CQ-0736, has demonstrated superior performance to the RAS inhibitor RMC-6236 (U.S. National Priority Voucher Program) in preclinical animal models.